Open access

NEWS - Endocrinology

Prognostic Implications of Single-Sample Confirmatory Testing for Undiagnosed Diabetes: A Prospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentaries: Diagnosing Diabetes From a Single Blood Sample – Johns Hopkins Bloomberg School of Public Health, via NewsWise (free) AND One Blood Test Might Be Enough to Diagnosis – HealthDay (free) AND Diabetes Dx Predicted Accurately with Single Blood Sample – MedPage Today (free registration required)

“The standard practice of repeat blood tests may not always be necessary, a new study suggests” (from Johns Hopkins Bloomberg School of Public Health)


The association between food insecurity and incident type 2 diabetes in Canada: A population-based cohort study – PLOS One (free)

Commentary: Food insecurity linked to type 2 diabetes risk – Reuters (free)

“Canadians who cannot afford to eat regularly or to eat a healthy diet have more than double the average risk of developing type 2 diabetes” (from Reuters)


A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks – Diabetes Care (free) (via @Abraham_RMI)

Related guideline: Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians (free)

“Clinicians should aim to achieve an HbA1c level between 7% and 8% in most patients with type 2 diabetes” (from ACP Guideline, prompting the Editorial)


High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial – Circulation (free)

With a median follow-up of 3.9 years, high-dose as compared with low-dose pitavastatin significantly reduced the risk of the primary end point (4.3% vs 5.4%; NNT = 90), a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization.


Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis – JAMA (link to abstract – $ for full-text)

Commentaries: Patients With Highest LDL Levels Benefit Most From Lipid-Lowering Drugs – MedicalResearch.com (free) AND New Study Finds that Statins Prevent Cardiovascular Deaths – Science Based Medicine (free) AND Meta-Analysis: ‘Floor’ for Lipid-Lowering Mortality Benefits May Be Real – MedPage Today (free registration required)

“In meta-analyses of LDL-C lowering drug trials, we found that total and cardiovascular mortality were reduced only when the mean baseline LDL-C in the trial was >100 mg/dl” (from MedicalResearch.com)


What We Know (and Don’t Know) About How to Lose Weight – The New York Times (10 articles per month are free)

“One conclusion from a much-discussed study: The best diet is the one you can stick to”.


#ACC18 – The ODYSSEY Trial Ends Well— But Will It Be Enough? – Cardiobrief (free) AND Ten Quick Thoughts on ODYSSEY – John Mandrola, via Medscape (free registration required)

“An absolute risk reduction of 1.6% in the primary endpoint translates to a number needed to treat of 64. Using the current price of $14,500 per year, Kaul calculated that preventing one event over the trial period of almost 3 years would cost about $2.6 million” (via John Mandrola). This study was presented at #ACC18 and has not been published yet. Among the many commentaries, these two were selected for a balanced point of view.


Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: a systematic review and meta-analysis – Diabetes Research and Clinical Practice (link to abstract – $ for full-text)

“Carbohydrate-restricted diets, associated with reductions in HbA1c of around 0.4% in short term” (via @kamleshkhunti see Tweet)


It’s poverty, not individual choice, that is driving extraordinary obesity level – The Conversation (free)

“Statistics point remorselessly towards obesity being a symptom with an underlying social cause”.


Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial – The Lancet (link to abstract – $ for full-text)

The mean number of hypoglycemic events per 28 days was reduced from 10.8 to 3.5 among patients in the continuous glucose monitoring group and from 14.4 to 13.7 among control group participants.


Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies – Progress in Neuro-Psychopharmacology and Biological Psychiatry (link to abstract – $ for full-text) (via @psychopharmacol see Tweet)

“These findings provide preliminary evidence that atypical antipsychotics cause insulin resistance and weight gain directly, independent of psychiatric disease and may be associated with length of treatment”.


Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis – Diabetic Medicine (free)

Source: ACP Journal Wise ($)

“Metformin was associated with lower gestational weight gain and a lower risk of pre-eclampsia compared with insulin”


Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals – JAMA Cardiology (free)

Commentary: Omega-3 Supplements Don’t Protect Against Heart Disease – The New York Times (10 articles per month are free)

Omega-3 fatty acids did not prevent fatal or nonfatal coronary heart disease or any major vascular events.


Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials – Journal of the American Heart Association (free)

PCSK9 inhibitors were associated with reduced incidence of myocardial infarction (2.3% vs 3,6%), stroke (1.0% vs 1.4%) and coronary revascularization (4,2% vs 5,8%). Overall, no significant change was observed in cardiovascular or all-cause mortality.


Page 1 of 3123

Stay updated in your specialty!

No spam, just news
Unsubscribe with one click